Background Scarce data are available on the use of vedolizumab in children with inflammatory
bowel disease (IBD). We aimed to evaluate the safety, effectiveness, and dosing of …

Background Vedolizumab is effective for inducing and maintaining remission in adults with
inflammatory bowel disease (IBD); however, there is limited pediatric data. This study aimed …

Objectives: Colectomy rates following acute severe ulcerative colitis have plateaued around
20% despite intravenous corticosteroid and intensified anti-tumor necrosis factor (TNF) …

Objectives The impacts of missing data in comparative effectiveness research (CER) using
electronic health records (EHRs) may vary depending on the type and pattern of missing data…

Objectives: Tofacitinib, a selective Janus kinase inhibitor, effectively induces and maintains
remission in adults with inflammatory bowel disease (IBD), but data are limited in children. …

Background Serum infliximab (s-IFX) levels, antibodies to IFX (ATI), and inflammatory markers
are important in predicting clinical outcomes in adults, but their roles in pediatric Crohn's …

Background Infliximab and adalimumab are the only biologics thus far approved for paediatric
patients with inflammatory bowel disease (IBD), so other biologics, such as vedolizumab, …

Background Tofacitinib has recently been approved for treatment of moderate-to-severe
ulcerative colitis (UC) in adults, yet pediatric data are limited. This international multicenter study …

Background Patients enrolled in randomised controlled trials (RCTs) may differ from the
target population due to restricted eligibility criteria. Aim To compare treatment response to …

Importance The profile of gastrointestinal (GI) tract outcomes associated with the postacute
and chronic phases of COVID-19 in children and adolescents remains unclear. Objective To …